NEW YORK (GenomeWeb) – Results from the Phase II SUMMIT trial, presented this weekend at the annual meeting of the American Association for Cancer Research in Washington, DC, have upheld the expectation that mutation status, regardless of tumor type or location, can contribute to response to targeted therapy.

The findings reiterate the importance of basket clinical trials that recruit patients not solely based on the location or clinical presentation of their tumor, but on the presence or absence of a particular mutation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.  

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.